Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
6 Web-based Lawful Administrations: Extensive Surveys and Elements - 2Dominating the Remote Work Way of life: Individual Systems
- 3Building Tough Connections: Individual Bits of knowledge on Association
- 4Careful Living: Embracing the Current Second
- 5Oldest sequenced RNA reveals details about a mammoth’s final moments 40,000 years
- ‘Raising 10 red flags’: Is Israel’s army exhausted?
- Figure out How to Pick a Crematorium: Key Contemplations.
- Shakira's 2026 'Las Mujeres Ya No Lloran' U.S. Tour: How to get tickets, prices, dates and more
- The Way to Business: Startup Illustrations Learned
- After harsh winter, Ukrainians find joy in releasing bats rescued from war
- Mussolini's summer villa on Adriatic coast sold for €1.2 million
- Instructions to Decide the Best SUV Size for Seniors
- Instructions to Amplify Certifiable Experience While Chasing after an Internet Advertising Degree
- Figure out How to Back Your Rooftop Substitution
